Presentations on ROS1+ Cancer at IASLC #WCLC2018


Members of The ROS1ders will be attending The International Association for the Study of Lung Cancer’s (IASLC) annual World Conference on Lung Cancer (WCLC) in Toronto, Canada, September 23-26, 2018.  The Twitter hashtag for the conference is #WCLC2018. Presentations that will mention ROS1+ cancer are listed below.  The abstract book containing these and other WCLC … Continue reading Presentations on ROS1+ Cancer at IASLC #WCLC2018

Should we combine TKIs and immunotherapy?


Some researchers think combining immunotherapy and certain targeted therapies called tyrosine kinase inhibitors (TKIs) may be too toxic for patients. This Phase 1/2 study supports that idea. It combined nivolumab and full-dose crizotinib in ALK+ non-small cell lung cancer, and was discontinued for safety reasons when 38% of the first 13 patients developed liver problems … Continue reading Should we combine TKIs and immunotherapy?

#ROS1 Presentations at ESMO 2017


The European Society for Medical Oncology will hold their annual Congress in Madrid, Spain, on September 8-12 this year.  The three presentations that will discuss ROS1 specifically are listed below (you can see the complete abstracts by clicking on the presentation title). 1308PD – Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small … Continue reading #ROS1 Presentations at ESMO 2017

TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation


A TP Therapeutics, Inc. drug designated TPX-0005 received FDA Orphan Drug Designation on June 27, 2017.  The first patient enrolled in March 2017 in the TPX-0005 Phase 1 clinical trial for advanced solid tumors with ROS1, ALK, and NTRK rearrangements. Here is the clinical trial listing on clinicaltrials.gov: NCT03093116:  A Study of TPX-0005 in Patients … Continue reading TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation